2023 World Conference on Lung Cancer (Posters)-EP13.04. Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer

EP13.04. Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer - PDF(Slides)

Pdf Summary

This study aimed to review the clinical features, treatment, and outcomes of patients with limited-stage small cell lung cancer (SCLC) and extrapulmonary small cell carcinomas (EPSCC). EPSCC represents a small percentage of SCLC cases and all cancers overall. The treatment of EPSCC is often based on data from SCLC. The study was a real-world retrospective cohort study conducted at four Australian hospitals. The eligibility criteria included a diagnosis based on biopsy morphology and immunohistochemistry, and it also included cases with mixed histology of small cell and other carcinoma. The study included 94 patients, with 82 having SCLC and 12 having EPSCC. The most common form of treatment for SCLC was definitive chemoradiotherapy, while for EPSCC it was definitive surgery with adjuvant therapy. The median overall survival (OS) was 25.8 months for SCLC and 16.2 months for EPSCC. The study concluded that the survival outcomes of patients with limited-stage EPSCC may differ depending on the origin of the cancer. Multi-modal therapy involving local therapy and platinum-based chemotherapy could optimize outcomes for patients with limited-stage EPSCC. However, the choice of local therapy may be dependent on the origin of the extrapulmonary cancer. Real-world data is valuable in understanding these rare cancers, as prospective studies are challenging in limited-stage EPSCC.

Asset Subtitle

Daniel Liem

Meta Tag

Speaker Daniel Liem

Topic SCLC & Neuroendocrine Tumors: LS-SCLC

Keywords

limited-stage small cell lung cancer

extrapulmonary small cell carcinomas

clinical features

treatment

outcomes

real-world retrospective cohort study

Australian hospitals

biopsy morphology

immunohistochemistry

mixed histology